# Factors Influencing the Use of G-CSF in Drug-Induced Agranulocytosis

## TL;DR

This review discusses factors affecting the use of G-CSF in treating drug-induced agranulocytosis, a rare but dangerous condition.

## Contribution

The paper provides a comprehensive review of factors influencing G-CSF use and highlights gaps in clinical trial evidence.

## Key findings

- G-CSF reduces neutropenia duration and hospitalization in drug-induced agranulocytosis.
- Mortality impact of G-CSF remains uncertain despite observational evidence.
- Treatment decisions should consider neutrophil count, infection severity, age, and comorbidities.

## Abstract

Drug-induced agranulocytosis is a rare but life-threatening adverse reaction associated with numerous non-chemotherapy drugs. Management relies on immediate drug withdrawal, infection control, and, in selected patients, administration of granulocyte-colony stimulating factor (G-CSF). This review summarizes current knowledge on the determinants of epidemiology, clinical presentation, hematologic and biologic features, comorbidities, and outcomes influencing the decision to introduce G-CSF in drug-induced agranulocytosis. Evidence from observational studies and meta-analyses suggests that G-CSF shortens neutropenia duration and hospitalization, although its impact on mortality remains uncertain. The decision to use G-CSF should consider initial neutrophil count, presence of severe infection or sepsis, age, and comorbidities. Despite the accumulated experience, randomized controlled trials are still lacking, and treatment algorithms remain empirical.